Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.
Hi Twix, I'm afraid I can't be certain of those numbers. The 600 labs was given to me as part of my Inside information prior to coming in, but I can't find any reference to 700,000 tests per year. This would equate to around £70M net profit and early projections weren't that high! I will do some digging. I would imagine the Downs Syndrome screening would relate to standard hormone screening, no the amniocentesis screening which we would be directly replacing and which wouldn't be done by the external labs as I understand. My hope for this would be to actually replace the standard basic screening with a complete genetic screen from an in-vitrio blood test - or in the more near term a lower cost to the test which would allow routine blood screening fro downs rather than the in-accurate hormone screening. If we could do a genetic screen for all markers tested by the amniocentesis and create a one-stop routine in-vitrio genetic screen we'd be invested in a multi-billion £ business. That's the future I hope, and in the meantime more specific marker tests for chromosomal disorders. I'm getting somewhat out of my depth in this bit, but the potential for this technology is blindingly obvious.
inkisblue, why do you feel the authorities would baulk at the price? Amniocentesis (existing invasive needle procedure): Min £800 depending on trust Competitors: £400 - £450 for specialist lab abroad Prematiha: £300 - £350 Price is competitive and has a quicker turn around. Sorry you've based your sale decision on incorrect info.
Vanvagabond, This is a spot on explanation. They are targeting about 600 UK labs with this model.
Sorry, should have been second *that Ian, useful posts thankyou
Second test. Thanks Ian
You might need your cryptography wheel to understand his usually brief posts though.. :) I have learned if he sends one link, it's usually the result of a good deal of research on the subject and his conclusion is summed up by the link he sends. Just a little help on the interpretation when it comes!
Does very good research, so when it comes out it's best to think carefully upon it, good or bad. Although I have a sneaky feeling that he's found some very positive news - not wanting to spoil your entry price Alexios? hee hee. You might get a lucky entry if there's a serious seller depressing the price in the short term, but you'll need to be careful about missing the chance - you saw the speed of the rise earlier. However AIM often rewards the patient. I agree that the 0.5 or 50p in new money is going to be a shoe-in for the team - it's great they have such a good target to hit. 0.5 for 30 consecutive days. I think that would suit us all, but it's always nice to see the management teams goals aligned with ours.
Hi, - Current cost of amniocentesis is £800 at least depending on NHS Trust - Competitive product is £400, but involves sending abroad to China to US labs. And specialist service. - Premaitha Health product costs £200 to UK labs which they hope to market to around 600 who will add margin and sell for no more than £350 top end. Has cost savings as well as patient benefits.
response from the market indicated on opening.
Thanks Alexios, that's very interesting and the market cap growth is consistent with what your TA was telling you too, which is rather pleasing! Good stuff, note that Rupert Lywood and Charles Roberts are both personal shareholders and significant stakeholders through Zoragen Biotechnologies LLP, Animatrix Capital LLP and Loxbridge Research LLP (47.6% between those three companies and personal holdings). Basically they are pretty much all the sticky money in this venture. There is 55% do shares not in public hands and taking these investors into account that's 62.6% in total that will be in this for the long haul. Bearing in mind also people like myself partaking in fundraising that is sticky money, you can understand why it's being spoken on 10% of shares being traded here. No wonder they anticipate such a large growth in mcap along with a bright future for the products indeed.
Fantastic to see that link vanvagabond. Really good news. Seeing a big opportunity here, and I've no doubt the market will too. Don't forget also the private health sector which is getting bigger and bigger. This will be a shoe-in as a pre-natal test as par for the course.
They are, ELJ7 might not be well known on many boards, but not only can he read a balance sheet and fundamentals well, but actually takes the time to research his stock picks. One to pay attention to.
Sorry EGM
Yep, 4th July will be when they are admitted for trading. All subject to approval at AGM of course.
Hi Elj7, always good to have your considered opinion on something. The. £400 refers to the same test as we have, but it's currently only available from labs in China and I believe in the US which might be off considering what you said. But I believe the lab is there even if they don't make it available to us citizens. Premaitha is the first company to have this in Europe, but despite developing test, my understand is that there is no proprietary IPR on it. However they will be first to market and will sell it for around £200 to the 600 odd UK labs initially capable of processing it, who will in turn sell it on for and £350 at the top end. I believe but don't quote me on it, that the test costs around £100 to produce. So it's slightly cheaper than the current £400 test that also involves sending abroad. Obviously there is sufficient margin in there for Uk labs to reduce costs if they want. The real test to compare it with right now though is the amniocentesis itself which is the only other local alternative to the Premaitha test which costs a minimum of £800. As you rightly say there is a basic screening test right now of ultrasound and hormonal analysis. This will not replace the hormonal analysis, but I do see it in time and with economy of scale being the one and only early stage pre-natal blood test. Why screen to see what yours odds of an issue are when you can just screen for genetic markers with almost complete accuracy. The hormone markers are known to be nothing more than very general indicators anyway and are often wrong in that they highlight cases for concern when there is none, and miss the many pregnancies that go on to have children with birth defects not previously known. That is not to say that the current 700,000 born with Downs for example are as a result of tests going wrong, there are of course parents who decide to not have the test as it would make no difference to their personal decision anyway, this is not an ethical question; just changing the quality and invasive ness of what's already available. With the current normal screening, a 1 in 20,000 chance or greater is considered acceptable risk for Downs for example. 1 in 1,000 is very high risk. This puts into perspective both our kids having 1 in 16 results which was off the scale and unheard of, almost a given they had Downs. And yet neither did after the awful amniocentesis. The initial screening was wildly inaccurate, and the awful invasive test not needed. I know we are here to make a return, but I note a couple of posters have personal experience of this, and it was an agonising decisions to have the procedure for us, and it felt awful watching the consultant put that needle into your wife's abdomen where your unborn baby was, praying it will be still. Sounds a bit melodramatic, but this will be fantastic. European market alone is huge and much more opportunity worldwide, no reason why the US can't come further dow
as below, I participated in the fund-raising at 11p. And intend to hold. I personally want this company to do very well. It's both a financial winner and will remove a very distressing procedure from our hospitals and those abroad. Very promising - the board will take this forward. Look up profiles of Adam Reynolds, David Evans and Stephen Little.
You can only participate if you are already a shareholder and the amount you can buy depends on how big your holding is. So no rush, you'll get your chance whatever, hope there's a rush on the general market shares though. And no to the Q below, they won't end up with a value of 11p, that only related to the open offer shares price you buy at, as soon as you've bought them, their value will be whatever the current ASAP is e.g. 14p bid and 17p ask on current price. So instant profit, highly recommend taking the offer. Your existing holding will just become consolidated e.g. 1,000,000 shares will become 10,000 shares, but overall value will remain the same. Consolidation is a good thing and means the price will move faster with less shares in issue. Hope this is clearer, shouldn't be trying to help with a hangover!
You interested here Alexios?
Yes, of course it is. Sorry. Thick head today! ;)
That's the price of the placing (fund raising) shares, it doesn't mean all your existing shares are priced here. Effectively it a a discount to attract large investment in to raise a specific sum of money. Think of it as a bulk discount price down Costco! It's normal practice, although admittedly this is a larger discount that is usual to raise funds. What's good here is that existing shareholders can participate in this price too via the open offer, I really don't like companies that don't involve existing shareholders in fund raising (most of them) to reward them with the discount for their loyalty.